TheraCryf Research and Development Day
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
TheraCryf Research and Development Day - 13 June 2024
Alderley Park, 13 June 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that it is holding a Research and Development update event today at 09:30am.
The management team and external speakers will be providing an update on TheraCryf, including the Chronos acquisition and update on the integration; discussion about the clinical programme in glioblastoma and the preclinical programmes in neuropsychiatry. The session will also include a discussion about market potential and the ongoing strategy.
Speakers will include members of the TheraCryf (and former Chronos) management and scientific team, and external speakers including Dr Marjolein Geurts, neuro-oncologist and Dr Wouter Vanbilloen MD, neurology resident from Erasmus University Medical Center.
Please note that the Erasmus team will provide a new update from their research on the combination of SFX-01 and radiation in certain glioblastoma cells derived from patients. They have observed a positive combination effect of SFX-01 and radiation which has also been observed with SFX-01 in laboratory models of glioblastoma in other centres.
The event will be held at the offices of Instinctif Partners located at 65 Gresham Street, London EC2V 7NQ and is open to sell-side analysts and all existing and potential shareholders. Investors and analysts will be able attend the event in person (please register at TheraCryf@instinctif.com) or virtually via the Investor Meet Company platform HERE.
- Ends-
Enquiries
|
TheraCryf plc Dr Helen Kuhlman, CBO
|
+44 (0)1625 315 090 |
|
Cavendish Capital Markets (NOMAD and Broker)
|
+44 20 7220 0500 |
|
Instinctif Partners Melanie Toyne-Sewell / Jack Kincade |
+44 207 457 2020 |
About TheraCryf plc
TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications such as neurodevelopmental disorders, glioblastoma*, addiction, anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate compelling data sets to proof of concept and/or later phase II to partner its clinical programmes with mid-size to large pharma. As well as a number of industry partnerships with companies, including Stalicla, in neurodevelopment disorders and has sourced programmes from companies such as Takeda and Shire, the Company has worked with and has ongoing collaborations with major universities, hospitals and government organisations such as the University of Manchester, Sapienza (Università di Roma), Kings College London and University of Connecticut.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF.
For further information, please visit: www.theracryf.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund